GLP-1 Patient Support Market Set to Hit $2.85 Billion by 2036, Driven by Onboarding Demand
The market for GLP-1 patient support services is growing fast. Fact.MR now pegs it at $545 million in 2026….
-
-
Altimmune’s Pemvidutide Reduces Heavy Drinking in Phase 2 Alcohol Use Disorder Trial
Altimmune’s investigational dual GLP-1/glucagon receptor agonist met its primary and key secondary endpoints in a mid-stage trial for alcohol…
-
Using Pre-Tax Accounts to Pay for GLP-1 Medications
GLP-1 medications can make a huge difference for your health, but paying for them out of pocket can feel…
-
Novo Nordisk Price Target Rises to $80 as Oral Wegovy Surpasses 3 Million Prescriptions
Novo Nordisk received an upgraded price target of $80, while market analysts assigned the stock a Modest Buy rating….
-
GLP-1 Weight-Loss Drugs May Weaken Other Medications, Emerging Research Suggests
Doctors are looking closely at how new weight-loss treatments mix with other pills. These medicines copy natural body signals…
-
GLP-1 Medications May Reduce Nail Biting, Emerging Reports Suggest
Nail biting is way more common than most people realize up to 30% of us do it. It’s a…
-
Medicare is Finally Covering Weight-Loss Drugs: What You Need to Know
About one in eight adults now takes a GLP-1 drug to help lose weight. For years, though, Medicare users…
-
Semaglutide Sustains Reduced Calorie Intake Beyond One Year
Even when people start feeling hungry again, semaglutide helps them eat fewer calories for over a year. A study…
-
Combination Therapy Offers Limited Additional Benefit in Type 2 Diabetes
Taking two common types of type 2 diabetes medications together might not protect your heart or kidneys any better…
-
Confectionery Consumption Trends Among GLP-1 Users
People taking GLP-1 medications are still buying and enjoying chocolate and candy on a regular basis. Recent research from…
